Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, announced on Tuesday that it has partnered with the Population Council to provide its VitalDose Drug Delivery Platform for a new Multipurpose Prevention Technology (MPT) Intravaginal Ring (IVR). This IVR is designed to offer both contraception and HIV protection and is currently undergoing a phase 1b clinical trial.

IVRs, which provide long-acting continuous drug delivery, offer advantages over daily oral doses, including improved convenience and patient adherence. Celanese's VitalDose Drug Delivery Platform, with over two decades of use in women's health, enables consistent and tunable elution for various active pharmaceutical ingredients (APIs).

The VitalDose Drug Delivery Platform has a proven track record in delivering controlled-release performance for a wide range of molecule types and is used in approved parenteral drug products globally.

Celanese Corporation produces differentiated chemistry solutions and specialty materials for various industries and applications, striving to create value for stakeholders while making a positive impact on communities and the world through The Celanese Foundation.

The Population Council is a research organisation focused on improving the health and well-being of underserved populations worldwide through research, evidence generation and innovative solutions.